Details of the Drug
General Information of Drug (ID: DM1LMFG)
Drug Name |
FAUC213
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
FAUC 213; 337972-47-1; FAUC-213; UNII-G8F040299R; CHEMBL310843; G8F040299R; 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine; GTPL974; CTK8E8281; DTXSID40187460; HMS3263F09; Tox21_501144; BDBM50102712; ZINC52541476; MFCD06798338; Pyrazolo(1,5-a)pyridine, 2-((4-(4-chlorophenyl)-1-piperazinyl)methyl)-; CCG-222448; LP01144; API0002679; NCGC00261829-01; NCGC00165795-01; NCGC00165795-02; RT-012699; FAUC 213, > J-019326; 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-pyrazolo[1,5-a]pyridine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 326.8 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References